These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 15081103)
21. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H J Med Virol; 2007 Nov; 79(11):1686-95. PubMed ID: 17854035 [TBL] [Abstract][Full Text] [Related]
22. [Recent trends in the therapy of hepatitis C]. Meschini A; Lucchetta MC; Fontana M; Nocchi S; Pace A; Grassi M Clin Ter; 2003; 154(3):181-91. PubMed ID: 12910808 [TBL] [Abstract][Full Text] [Related]
23. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C. McHutchison J; Sulkowski M J Viral Hepat; 2008 Jul; 15(7):475-81. PubMed ID: 18363672 [TBL] [Abstract][Full Text] [Related]
24. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection. Ferenci P; Formann E; Laferl H; Gschwantler M; Hackl F; Brunner H; Hubmann R; Datz C; Stauber R; Steindl-Munda P; Kessler HH; Klingler A; Gangl A; J Hepatol; 2006 Feb; 44(2):275-82. PubMed ID: 16338019 [TBL] [Abstract][Full Text] [Related]
26. Hepatitis C treatment update. Pearlman BL Am J Med; 2004 Sep; 117(5):344-52. PubMed ID: 15336584 [TBL] [Abstract][Full Text] [Related]
27. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover. Zeuzem S; Schmidt JM; Lee JH; von Wagner M; Teuber G; Roth WK Hepatology; 1998 Jul; 28(1):245-52. PubMed ID: 9657119 [TBL] [Abstract][Full Text] [Related]
28. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin. Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916 [TBL] [Abstract][Full Text] [Related]
29. Role of epoetin alfa in maintaining ribavirin dose. Afdhal NH Gastroenterol Clin North Am; 2004 Mar; 33(1 Suppl):S25-35. PubMed ID: 15081101 [TBL] [Abstract][Full Text] [Related]
30. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H J Hepatol; 2007 Mar; 46(3):403-10. PubMed ID: 17126448 [TBL] [Abstract][Full Text] [Related]
31. New therapies on the horizon for hepatitis C: are we close? De Francesco R; Rice CM Clin Liver Dis; 2003 Feb; 7(1):211-42, xi. PubMed ID: 12691468 [TBL] [Abstract][Full Text] [Related]
32. Hepatitis C virus: current understanding and prospects for future therapies. Rosen HR; Gretch DR Mol Med Today; 1999 Sep; 5(9):393-9. PubMed ID: 10462751 [TBL] [Abstract][Full Text] [Related]
34. Prospects for nucleic acid-based therapeutics against hepatitis C virus. Lee CH; Kim JH; Lee SW World J Gastroenterol; 2013 Dec; 19(47):8949-62. PubMed ID: 24379620 [TBL] [Abstract][Full Text] [Related]
35. Targets and tools: recent advances in the development of anti-HCV nucleic acids. Romero-López C; Sánchez-Luque FJ; Berzal-Herranz A Infect Disord Drug Targets; 2006 Jun; 6(2):121-45. PubMed ID: 16789875 [TBL] [Abstract][Full Text] [Related]
36. RNA as a target for developing antivirals. McKnight KL; Heinz BA Antivir Chem Chemother; 2003 Mar; 14(2):61-73. PubMed ID: 12856917 [TBL] [Abstract][Full Text] [Related]
37. Molecular therapies for viral hepatitis. Guha C; Shah SJ; Ghosh SS; Lee SW; Roy-Chowdhury N; Roy-Chowdhury J BioDrugs; 2003; 17(2):81-91. PubMed ID: 12641487 [TBL] [Abstract][Full Text] [Related]
40. Recent advances in prevention and treatment of hepatitis C virus infections. Wang QM; Heinz BA Prog Drug Res; 2000; 55():1-32. PubMed ID: 11127961 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]